BACKGROUND
Smoking is associated with the development and progression of cardiovascular disease, and it increases by two to three fold the risk of coronary artery disease (CAD). 1, 2 In the Brazilian population, smoking has an estimated prevalence of 14.5%, 3 and is a risk factor in almost half of acute myocardial infarction (AMI) patients. [4] [5] [6] [7] [8] [9] [10] The association of smoking with better clinical outcomes in AMI patients undergoing fibrinolysis is known as the smoking paradox. This has been attributed to the heterogeneity of baseline clinical characteristics rather than to a beneficial effect of smoking. 4, [11] [12] [13] Some studies have explored the association between smoking and hospital mortality in patients undergoing primary angioplasty, and presented controversial results. 6, 8, 10, [14] [15] [16] [17] This study aimed to evaluate the association between smoking and hospital mortality in patients undergoing primary angioplasty.
METHODS

Study design and population
A single-center registry of all patients who underwent primary angioplasty for treatment of ST-segment elevation myocardial infarction (STEMI), from January to July 2014. Patients who self-declared being active smokers upon hospital admission were defined as smokers. Hospital mortality was defined as the occurrence of death during hospitalization up to 30 days after admission. The project was evaluated and accepted by the Ethics Committee of the organization (CAAE 47779915.0.0000.5039), and all principles of the Declaration of Helsinki of 1975 (revised in 2008) and norms of the resolution 466/2012 of the National Health Council were respected.
Inclusion and exclusion criteria
Patients older than 18 years, with ischemic time (defined as the elapsed time from onset of pain to the first contact with the emergency department of the hospital) of less than 12 hours, and with clinical and electrocardiographic diagnosis of STEMI were included. Patients who did not undergo diagnostic cardiac catheterization for any reason, and those who had other diagnoses after the procedure (Takotsubo, aortic dissection, AMI with normal coronary arteries and coronary vasospasm) were excluded.
Procedures
All patients followed the standard treatment flowchart of the organization, with administration of acetylsalicylic acid and the second antiplatelet agent (600mg clopidogrel, 180mg ticagrelor, or 60mg prasugrel) at the discretion of the emergency cardiologist. The procedures were performed predominantly via the femoral artery, with administration of 70 to 100U/kg of unfractionated heparin during the intervention. Baseline clinical variables (demographic characteristics, risk factors for coronary disease, drug therapy, time of ischemia, and electrocardiographic pattern) and angiographic and procedural characteristics were collected. Patients were divided into smokers and non-smokers groups.
Statistical analysis
Statistical 
RESULTS
A total of 193 patients were included, of which 59 (30.6%) were female. The mean age was 62±11.9 years. The mean time from onset of pain to hospital arrival was 342.6±159.3 minutes. The prevalence of smoking was 45.1%. The angiographic and procedural characteristics are pre sented in table 2. The pattern of single-, two-, and three-vessel disease was 38.8%, 34.7%, and 21.8%, respectively. The right coronary artery was the most frequently identified culprit artery (49.2%), followed by the left anterior descending artery (43.5%), and the circumflex artery (6.2%). There was one infarction due to occlusion of the left main coronary artery (LMCA) (0.5%), and one due to saphenous vein graft occlusion (0.5%). Nineteen patients (9.8%) had initial Thrombolysis in Myocardial Infarction (TIMI) flow grade 3; thrombus manual aspiration was used in 16.6% of cases, pre-dilation was performed in 71.5%, and the mean number of stents per patient was 1.3±0.6. In 14 patients (7.3%), angioplasty was performed without Results expressed as mean ± standard deviation or n (%). * The first serum creatinine level after admission was considered, ≥1.5 mg/dL; † time from onset of pain to admission at emergence room; ‡ value obtained from echocardiogram performed at 2 to 10 days after infarction. CAD: coronary artery disease; ECG: 12-lead electrocardiogram; CKMB: creatine-kinase iso-enzyme MB; ASA: acetylsalicylic acid; GP: glycoprotein; UFH: unfractionated heparin; ACEI: angiotensin converting enzyme inhibitors; BRA: angiotensin II receptor blockers.
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4 stent implantation. After primary angioplasty, 12 patients maintained final TIMI flow 0-1 (5.2%). There were no differences between smokers and non-smokers regarding the angiographic and procedural characteristics analyzed.
There was no difference in hospital mortality between smokers (5; 5.7%) and non-smokers (10; 9.4%) (p=0.346). The factors associated with hospital mortality were age ≥75 years, creatinine ≥1.5mg/dL, ejection fraction ≤35%, LMCA lesion, and final TIMI flow grade of 0 or 1 (Table 3) .
Smoking patients, compared to non-smokers, were younger, more often men, had lower body mass index, and lower prevalence of hypertension, dyslipidemia, diabetes mellitus, renal failure and anemia on admission; they also had a higher platelet count and were less often in Killip class 2 upon hospital admission. These results are consistent with other studies. Weisz et al. 6 published a subanalysis of the CADILLAC study, in which they showed that the mortality of STEMI patients treated with reperfusion is not related to smoking. In the Brazilian population, this association was studied by Curado et al., 18 through the analysis of 20,319 STEMI patients undergoing primary or salvage angioplasty, in the Brazilian National Registry of Cardiovascular Interventions (CENIC, http://www.corehemo.net/). Similar to the aforementioned studies, smoking did not show a protective effect after multivariate analysis, with the conclusion that the results were due to differences found in the clinical and angiographic characteristics between smokers and non-smokers. Addad et al. 8 evaluated this association in a French population registry, including 688 patients, in which they found a prevalence of 70.1% of active smoking in AMI patients undergoing thrombolysis or primary angioplasty. Mortality was significantly lower among smokers in case of thrombolysis, compared to non-smokers (5.3% vs. 13.0%; p=0.008). However, in the primary angioplasty group, there was only a trend towards lower mortality among smokers (10.0% vs. 17.6%; p=0.07). After multivariate analysis, cardiogenic shock (p<0.0001), anterior wall AMI (p=0.03), and active smoking (p=0.03) remained as independent predictors of mortality in case of thrombolysis. These results show that baseline clinical differences, such as younger age at AMI presentation, lower prevalence of comorbidities and of risk factors in the smoking population with AMI, can explain the occurrence of the smoking paradox phenomenon, but there may be other factors that influence this association.
An important feature of this registry was that most patients used ticagrelor, whereas previous studies have used clopidogrel as the second antiplatelet agent. 4, 6, 8, 18 It is known that smoking has an effect on the pharmacodynamics of P2Y 12 receptor inhibitors. Smoking induces CY-P1A2, one of the cytochrome P450 isoenzymes responsible for the activation of thienopyridines, influencing the antiplatelet efficacy of these drugs. [19] [20] [21] Clopidogrel is the drug most studied in this context, but ticagrelor and prasugrel may also be influenced by this same mechanism.
Clopidogrel and prasugrel are inactive prodrugs, which bind irreversibly to the platelet P2Y 12 receptor, and inhibit platelet activation and aggregation by adenosine diphosphate (ADP), 22 whereas ticagrelor is an active drug, which inhibits reversibly the P2Y 12 receptor, has a half-life of 12 hours, does not need hepatic metabolic activation, and is less influenced by cytochrome P450. 23 Gagne et al. 21 published a meta-analysis in which clopidogrel was associated with a 25% reduction in major adverse cardiac and 
DISCUSSION
The present registry showed no association between smoking and hospital mortality in patients undergoing primary angioplasty, contrary to the smoker's paradox. The main findings of the study were: no association between smoking and age at the time of AMI, with a mean age of 62.3±13.0 years; long elapsed time between the onset of symptoms and admission to hospital, with a mean of 342.6±159.3 minutes; high success rate of primary angioplasty (93.8%); the majority of patients were male; similar baseline characteristics between groups, statistically differing only in the use of ACE inhibitors or BRA (97.7% vs. 84.9%; p=0.003), and dyslipidemia (34.5% vs. 16.0%; p=0.003), higher among smokers; use of the main classes of the second antiplatelet agent, with a higher prevalence of ticagrelor (72.1%), followed by clopidogrel (40.0%) and prasugrel (5.0%).
The absence of association between smoking and other baseline clinical characteristics may justify the non-association between smoking and mortality. Currently, the estimated smoking prevalence in the Brazilian population is around 14%. In this registry, approximately half of MI patients were smokers, reinforcing the causal relationship between smoking and AMI risk in the current context. 3 In a subanalysis of the HORIZONS-AMI study, Goto et al. 4 evaluated the impact of smoking in STEMI patients who underwent primary angioplasty. They randomized more than 3,500 patients, of whom half were smokers. They found that mortality was lower in smokers, but this finding was not sustained after adjustment of variables.
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ce rebrovascular events in smokers, but only 8% in the non-smoker group. Subsequent evaluations of the TRITON-TIMI 38 and TRILOGY-ACS studies showed that prasugrel was more effective than clopidogrel in reducing cardiovascular risk in patients with acute coronary syndrome who were smokers, but not in non-smokers. 19, 24 Reduction in final TIMI flow grade 0 or 1, death, or recurrent AMI outcomes with the use of prasugrel and ticagrelor was 29% and 17% in smokers, and 8% and 11% in non-smokers, respectively, when compared to clopidogrel. 21 This effect of smoking on these drugs may also influence the rates of bleeding complications associated with both thrombolytic and primary angioplasty, attenuating potential improvement in ischemic outcomes. 21 Although the antiplatelet effect of the new P2Y 12 receptor inhibitors appears to be more intense in smokers, in the studied population, most of whom used ticagrelor as the second antiplatelet agent, no association with hospital mortality was observed.
A Brazilian study which evaluated the clinical profile of young AMI patients (<45 years) undergoing primary angioplasty showed that this population had a high prevalence of modifiable risk factors, notably smoking, which was present in 72.2% of patients studied. 25 Larsen et al. 26 published an analysis on AMI patients undergoing primary angioplasty, with age-stratified data, comparing the prevalence of smoking in the study population and in the general population. Smoking was present in 46.43% of studied population. Patients undergoing angioplasty were more likely to be smokers (OR 3.4; 95%CI 3.3-3.4), with greater probability of smoking in young patients (OR for age <35 years 11.4; 95%CI 10.0-12.8). Relative reductions by 10%, 50% and 75% in smoking are predicted to prevent 109, 544 and 815 cases of AMI, with the conclusion that smoking continues to be a powerful risk factor for AMI, especially in the younger population. Some limitations of this study should be noted, such as a single-center setting that limits external validity; the nonavailability of data about smoking load and time of smoking, which could interfere in the association between smoking and hospital mortality; and its observational nature, which limits the evaluation of causality, although, from an ethical point of view, it would be impossible to explore this association of causality through randomized trials.
CONCLUSION
There was no association between smoking and hospital mortality in patients undergoing primary angioplasty. Advanced age, renal dysfunction, left main coronary artery lesion, left ventricular dysfunction, and procedural failure were associated with higher mortality at 30 days.
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